Michael J. Dascombe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael J. Dascombe has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Anthony M. Dyas
Faculty of Life Sciences, Stopford Building 1.124, The University of Manchester, Oxford Road, Manchester M13 9PT, U.K., School of Chemistry, University of Reading, Reading RG6 6AD, U.K., The Medicinal Chemistry Research Group, The School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool L3 3AF, U.K., Faculty of Science, Department of Biochemistry, Mahidol University, Bangkok 10400, Thailand, and Department of Chemistry, University of Hertfordshire, Hatfield AL10 9AB, U.K.
1 shared publication- Fyaz Mahmood Daud Ismail
Medicinal Chemistry and Natural Products Research Group, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, James Parsons Building, Byrom Street, Liverpool L3 3AF, United Kingdom
1 shared publication Harry Morris
Faculty of Life Sciences, Stopford Building 1.124, The University of Manchester, Oxford Road, Manchester M13 9PT, U.K., School of Chemistry, University of Reading, Reading RG6 6AD, U.K., The Medicinal Chemistry Research Group, The School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool L3 3AF, U.K., Faculty of Science, Department of Biochemistry, Mahidol University, Bangkok 10400, Thailand, and Department of Chemistry, University of Hertfordshire, Hatfield AL10 9AB, U.K.
1 shared publicationMichael G. B. Drew
Faculty of Life Sciences, Stopford Building 1.124, The University of Manchester, Oxford Road, Manchester M13 9PT, U.K., School of Chemistry, University of Reading, Reading RG6 6AD, U.K., The Medicinal Chemistry Research Group, The School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool L3 3AF, U.K., Faculty of Science, Department of Biochemistry, Mahidol University, Bangkok 10400, Thailand, and Department of Chemistry, University of Hertfordshire, Hatfield AL10 9AB, U.K.
1 shared publicationMichael Lloyd
Faculty of Life Sciences, Stopford Building 1.124, The University of Manchester, Oxford Road, Manchester M13 9PT, U.K., School of Chemistry, University of Reading, Reading RG6 6AD, U.K., The Medicinal Chemistry Research Group, The School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool L3 3AF, U.K., Faculty of Science, Department of Biochemistry, Mahidol University, Bangkok 10400, Thailand, and Department of Chemistry, University of Hertfordshire, Hatfield AL10 9AB, U.K.
1 shared publicationPamela Carr
Faculty of Life Sciences, Stopford Building 1.124, The University of Manchester, Oxford Road, Manchester M13 9PT, U.K., School of Chemistry, University of Reading, Reading RG6 6AD, U.K., The Medicinal Chemistry Research Group, The School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool L3 3AF, U.K., Faculty of Science, Department of Biochemistry, Mahidol University, Bangkok 10400, Thailand, and Department of Chemistry, University of Hertfordshire, Hatfield AL10 9AB, U.K.
1 shared publication
Latest Publications
- 26 July 2005
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (17) , 5423-5436
Mapping Antimalarial Pharmacophores as a Useful Tool for the Rapid Discovery of Drugs Effective in Vivo: Design, Construction, Characterization, and Pharmacology of Metaquine
Resistant strains of Plasmodium falciparum and the unavailability of useful antimalarial vaccines reinforce the need to develop new efficacious antimalarials. This study details a pharmacophore model that has been used to identify a potent, soluble, orally bioavailable antimalarial bisquinoline, metaquine (N,N‘-bis(7-chloroquinolin-4-yl)benzene-1,3-diamine) (dihydrochloride), which is active against Plasmodium berghei in vivo (oral ID50 of 25 μmol/kg) and multidrug-resistant Plasmodium falciparum K1 in vitro (0.17 μM). Metaquine shows strong affinity for the putative antimalarial receptor, heme at pH 7.4 in aqueous DMSO. Both crystallographic analyses and quantum mechanical calculations (HF/6-31+G*) reveal important regions of protonation and bonding thought to persist at parasitic vacuolar pH concordant with our receptor model. Formation of drug−heme adduct in solution was confirmed using high-resolution positive ion electrospray mass spectrometry. Metaquine showed strong binding with the receptor in a 1:1 ratio (log K = 5.7 ± 0.1) that was predicted by molecular mechanics calculations. This study illustrates a rational multidisciplinary approach for the development of new 4-aminoquinoline antimalarials, with efficacy superior to chloroquine, based on the use of a pharmacophore model.
- 26 July 2005
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (17) , 5423-5436
Mapping Antimalarial Pharmacophores as a Useful Tool for the Rapid Discovery of Drugs Effective in Vivo: Design, Construction, Characterization, and Pharmacology of Metaquine
Resistant strains of Plasmodium falciparum and the unavailability of useful antimalarial vaccines reinforce the need to develop new efficacious antimalarials. This study details a pharmacophore model that has been used to identify a potent, soluble, orally bioavailable antimalarial bisquinoline, metaquine (N,N‘-bis(7-chloroquinolin-4-yl)benzene-1,3-diamine) (dihydrochloride), which is active against Plasmodium berghei in vivo (oral ID50 of 25 μmol/kg) and multidrug-resistant Plasmodium falciparum K1 in vitro (0.17 μM). Metaquine shows strong affinity for the putative antimalarial receptor, heme at pH 7.4 in aqueous DMSO. Both crystallographic analyses and quantum mechanical calculations (HF/6-31+G*) reveal important regions of protonation and bonding thought to persist at parasitic vacuolar pH concordant with our receptor model. Formation of drug−heme adduct in solution was confirmed using high-resolution positive ion electrospray mass spectrometry. Metaquine showed strong binding with the receptor in a 1:1 ratio (log K = 5.7 ± 0.1) that was predicted by molecular mechanics calculations. This study illustrates a rational multidisciplinary approach for the development of new 4-aminoquinoline antimalarials, with efficacy superior to chloroquine, based on the use of a pharmacophore model.